Stockscreener 앱 받기
2.54
1.17%
-0.03
시간 외 거래:
2.53
-0.01
-0.39%
전일 마감가:
$2.57
열려 있는:
$2.55
하루 거래량:
556.22K
Relative Volume:
0.31
시가총액:
$219.55M
수익:
-
순이익/손실:
$-299.80M
주가수익비율:
-0.8944
EPS:
-2.84
순현금흐름:
$-217.49M
1주 성능:
+16.51%
1개월 성능:
+4.53%
6개월 성능:
-57.67%
1년 성능:
-41.61%
1일 변동 폭
$2.4469
$2.635
1주일 범위
$2.165
$2.655
52주 변동 폭
$1.845
$7.25
Acelyrin Inc Stock (SLRN) Company Profile
명칭
Acelyrin Inc
전화
805-456-4393
주소
4149 LIBERTY CANYON RD., AGOURA HILLS
SLRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLRN
Acelyrin Inc
|
2.54 | 219.55M | 0 | -299.80M | -217.49M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-09-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-09-05 | 개시 | H.C. Wainwright | Buy |
| 2023-05-30 | 개시 | Jefferies | Buy |
| 2023-05-30 | 개시 | Morgan Stanley | Overweight |
| 2023-05-30 | 개시 | Piper Sandler | Overweight |
| 2023-05-30 | 개시 | TD Cowen | Outperform |
모두보기
Acelyrin Inc 주식(SLRN)의 최신 뉴스
Acelyrin Shareholder Notice - Newsfile
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Acelyrin, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2024SLRN - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Acelyrin, Inc. (SLRN) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Acelyrin urges stockholders to vote for proposed merger with Alumis - Yahoo Finance
ACELYRIN urges stockholders to approve Alumis merger - Investing.com
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - The Manila Times
ACELYRIN, Inc. Urges Stockholders to Vote in Favor of Proposed Merger with Alumis Inc. Ahead of May 13, 2025 Meeting - Nasdaq
ACELYRIN Board Makes Final Push for Alumis Merger: 48% Ownership Deal at Stake in Critical May Vote - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Confident Outlook on Acelyrin-Alumis Merger Amid Shareholder Opposition - TipRanks
Acelyrin (SLRN) Faces Shareholder Opposition to Alumis Merger - GuruFocus
Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive
Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis - MSN
Acelyrin stock gains as Trium rebuffs M&A deal (SLRN:NASDAQ) - Seeking Alpha
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights - ADVFN
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms - Endpoints News
Revised merger terms boost ACELYRIN stake in Alumis deal By Investing.com - Investing.com South Africa
Alumis, ACELYRIN amend proposed merger pact - MSN
Alumis And Acelyrin Announce Amended Merger Agreement - marketscreener.com
Alumis Raises Share Consideration for Acelyrin Acquisition - marketscreener.com
ACELYRIN, INC. Amends Merger Agreement with Alumis - TipRanks
ACELYRIN and Alumis Announce Revised Merger Agreement Enhancing Stockholder Ownership and Value - Nasdaq
Alumis and ACELYRIN Announce Amended Merger Agreement - The Manila Times
Alumis Secures Major Immunology Merger: $737M Cash Runway Stretches to 2027, 62% Shareholders Back Deal - Stock Titan
Wheat Pushing Higher Ahead of Export Sales Release - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, SLRN, BECN on Behalf of Shareholders - The Malaysian Reserve
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener
Best Quantum Computing Stocks to Watch in 2025 - The Globe and Mail
ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times
Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – OPTN, SLRN, AKYA, SHYF - TradingView
Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia
Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders - The Malaysian Reserve
Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals
Indo-Asian News Service - Indo-Asian News Service (IANS)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN - Bluefield Daily Telegraph
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN, TURN, BHLB, MHLD - TradingView
Acelyrin Sees Stock Price Rise Amid Rights Plan - Los Angeles Business Journal
Acelyrin Inc (SLRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acelyrin Inc 주식 (SLRN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Murugan Amar | Chief Legal Officer |
Mar 17 '25 |
Sale |
2.74 |
3,913 |
10,737 |
121,587 |
| Mpofu Shephard | Chief Medical Officer |
Mar 17 '25 |
Sale |
2.74 |
3,211 |
8,811 |
121,789 |
0.39%
3.66%
자본화:
|
볼륨(24시간):